• Atmo secures full ownership of core IP for its ingestible gas-sensing capsule
• • RMIT University transfers all patents and IP in exchange for an equity stake in Atmo
• • Agreement enhances Atmo’s strong IP position ahead of regulatory milestones 

Atmo Biosciences, a leader in ingestible  capsule technology,  announced the successful assignment of its foundational patent  portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and  associated intellectual property (IP) related to the Atmo Gas Capsule to Atmo Biosciences in  exchange for an equity stake in the company. This IP was previously subject to an exclusive  royalty-based license agreement between Atmo and RMIT. 

The assignment marks a significant step in Atmo’s commercialization journey as it seeks  regulatory clearance with the U.S. Food and Drug Administration (FDA) following the successful  completion of a pivotal clinical study in a first indication last year. 

Originally developed through groundbreaking research by a team at RMIT University, the  ingestible gas-sensing capsule was first licensed by Atmo in 2018. Since then, Atmo has  advanced the technology from concept to clinical reality—developing, manufacturing, and  trialling the device to create a market-ready solution to aid the diagnosis of gastrointestinal  motility disorders. Atmo has since filed additional patents to expand its wholly-owned portfolio of IP in a variety of potential diagnostic and therapeutic applications, further  developing the ingestible capsule technology platform. 

University-Industry Collaboration Driving Innovation 

Professor Calum Drummond AO, Deputy Vice-Chancellor Research and Innovation and Vice President at RMIT, highlighted the importance of the partnership: 

"This agreement exemplifies our mission to translate academic research to benefit society. We  are particularly proud that several of our students and early career researchers played  instrumental roles in developing this technology at RMIT and have continued to contribute as  co-founders at Atmo Biosciences. The equity component of this agreement strengthens our  long-term collaboration, aligning our interests as Atmo continues to expand its platform  technology." 

Atmo Biosciences President and CEO Mal Hebblewhite emphasized the strategic significance  of the IP assignment: 

"This is a milestone for Atmo and for RMIT University. Having RMIT as a strategic shareholder  reinforces our shared commitment to bring this innovative technology to market. Full ownership  of our core IP further strengthens Atmo’s position as we advance toward regulatory clearance and commercialization, ensuring long-term value for our company and bringing benefit to the  patients we aim to serve."